Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_538518cb9af02dc5347029635c0f3feb |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 |
filingDate |
2020-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2022-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcff69c92296836657f85942c801fb19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32071da3beb059196b4b6dcabb36aec8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_335afbabc8b0b67541ea021dc23f8632 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6aeb6af501214b6d85c4b9f38285295b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27dd84458ab4e6cc009b03f46879b708 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b6fb50a9b0abbb5e65420a2bdc657e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f4212d3a92e6c9f5b55b9bdc4b7e9d7 |
publicationDate |
2022-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-11365239-B2 |
titleOfInvention |
Anti-SARS-COV-2 antibodies and uses thereof |
abstract |
Provided herein are modified anti-SARS-COV-2 antibodies or antigen binding fragments thereof having extended half life and optimized immune activities. Disclosed herein is also directed to pharmaceutical compositions comprising the same and a method for treating or preventing a disease in human patients that is caused by or related to the infection of SARS-COV-2. |
priorityDate |
2020-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |